You are here

Global Aliqopa (Copanlisib; Bayer) Drug Profile 2019: A Small Molecule Phosphoinositide 3-Kinase (PI3K) Inhibitor with High Selectivity for the p110-alpha/delta Catalytic Subunits

DUBLIN, July 1, 2019 /PRNewswire/ -- The "Aliqopa" report has been added to's offering.

Aliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial for normal B-cell development, and is subverted by follicular lymphoma (FL) to promote survival and growth. The p110-delta subunit is particularly important for the survival of indolent NHLs, and p110-delta as well as p110-alpha are hypothesized to be important for the survival of aggressive NHLs.

Analyst Outlook

With the accelerated approval of Aliqopa (copanlisib; Bayer) for the third-line treatment of follicular lymphoma (FL), Bayer positioned its phosphoinositide 3-kinase (PI3K) inhibitor in direct competition with Zydelig (idelalisib; Gilead), the first PI3K inhibitor approved for FL.

Bayer is also investigating Aliqopa in earlier lines of treatment and as a combination therapy with rituximab in the pivotal Phase III CHRONOS-2 ( identifier: NCT02369016), CHRONOS-3 ( identifier: NCT02367040), and CHRONOS-4 ( identifier: NCT02626455) trials. Indication for use with standard-therapy rituximab and expansion into earlier treatment settings would give Aliqopa an advantage over Zydelig, which failed to move beyond its single approval in third-line FL. In addition, Aliqopa may have to compete with PI3K inhibitors Copiktra (duvelisib; Verastem/Infinity/Yakult Honsha Co), INCB050465 (Incyte), and umbralisib (TG Therapeutics), which are currently in late-phase development for FL.

However, Aliqopa's commercial outlook in this indication may surpass other PI3K inhibitors due to its range of activity. Aliqopa is the only drug in its class that is a strong inhibitor of PI3K-alpha in addition to PI3K-delta, which could prove useful as PI3K-alpha is hypothesized to play a more prominent role as indolent non-Hodgkin's lymphomas (NHLs) become more aggressive.

Key Topics Covered:


  • Drug Overview
  • Product Profiles
  • Aliqopa: NHL: Follicular lymphoma (FL)

Figure 1: Aliqopa for follicular lymphoma - SWOT analysis
Figure 2: The authors drug assessment summary of Aliqopa for follicular lymphoma
Figure 3: Aliqopa sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017-26

Table 1: Aliqopa drug profile
Table 2: Aliqopa pivotal trial data in follicular lymphoma
Table 3: Aliqopa ongoing late-phase clinical trials in follicular lymphoma
Table 4: Aliqopa sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets